Cargando…
A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease that usually results in respiratory failure and death. Pirfenidone was approved as the first licensed therapy for IPF in Europe based on phase III trials where patients with a forced vital capacity (FVC) >50% o...
Autores principales: | Sköld, Carl Magnus, Janson, Christer, Elf, Åsa Klackenberg, Fiaschi, Marie, Wiklund, Kerstin, Persson, Hans Lennart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951637/ https://www.ncbi.nlm.nih.gov/pubmed/27435431 http://dx.doi.org/10.3402/ecrj.v3.32035 |
Ejemplares similares
-
Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden
por: Ferrara, Giovanni, et al.
Publicado: (2019) -
Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden
por: Ekström, Magnus, et al.
Publicado: (2019) -
Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016) -
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
por: Cottin, Vincent, et al.
Publicado: (2018) -
Annual and Post-Exacerbation Follow-Up of Asthma Patients in Clinical Practice – A Large Population-Based Study in Sweden
por: Sandelowsky, Hanna, et al.
Publicado: (2022)